D. Papadimos

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

Ksenija Nešić, John J. Krais, Yifan Wang, Cassandra J. Vandenberg et autres

PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance is common. Multiple resistance mechanisms have been described, including secondary mutations that …

au, us, gb, ca (code pays fourni par la source)

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

Nikki Burdett, Madelynne O. Willis, Ahwan Pandey, Laura Twomey et autres

Whole genome duplication is frequently observed in cancer, and its prevalence in our prior analysis of end-stage, homologous recombination deficient high grade serous ovarian cancer (almost 80% of samples) supports the notion that whole genome duplication provides a fitness advantage under the …

au (code pays fourni par la source)

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

Nikki Burdett, Madelynne O. Willis, Ahwan Pandey, Sián Fereday et autres

While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and primary peritoneal cancers (HGSC) has improved patient survival, resistance to PARP inhibitors frequently occurs. Preclinical and translational studies have identified …

au (code pays fourni par la source)

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cécile Le Page, Matthew J. Wakefield et autres

ca, au, us, de, gb, se (code pays fourni par la source)

Prognostic gene expression signature for high-grade serous ovarian cancer

Joshua Millstein, Timothy Budden, Ellen L. Goode, Michael S. Anglesio et autres

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust …

us, au, gb, ca, es, de, pl, fr (code pays fourni par la source)

Abstract P3-08-03: Dissecting the heterogeneity of metaplastic breast cancer: A morphological, immunohistochemical and genomic analysis of a large cohort

AE McCart Reed, Emarene Kalaw, Kátia Nones, Mark Bettington et autres

Abstract Although rare, Metaplastic Breast Carcinomas (MBC) account for significant global breast cancer mortality. This subgroup is extremely heterogeneous and by definition exhibits metaplastic change to squamous and/or mesenchymal elements, including but not limited to spindle, squamous, chondroid, osseous and rhabdomyoid elements. …

au (code pays fourni par la source)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke et autres

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical models and ovarian cancer …

au, us (code pays fourni par la source)

Identification of metastatic papillary thyroid carcinoma in FNA specimens using thyroid peroxidase immunohistochemistry

Paul Shield, StephenJ Crouch, D. Papadimos, Michael D. Walsh

INTRODUCTION: We evaluated immunohistochemical staining for thyroid peroxidase (TPO), a glycoprotein found in the apical plasma membrane of thyroid follicular cells, as a marker for metastatic PTC in FNA samples and compared results with thyroglobulin (Tg) and thyroid transcription factor 1 (TTF1) …

au (code pays fourni par la source)

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

Matthew S. Block, Robert A. Vierkant, Peter Rambau, Stacey J. Winham et autres

OBJECTIVE: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. PATIENTS AND METHODS: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival …

us, ca, Tanzanie, de, au, pl, br, es, gb, cn, dk (code pays fourni par la source)

Gata3 immunohistochemical staining is a useful marker for metastatic breast carcinoma in fine needle aspiration specimens

Paul Shield, StephenJ Crouch, D. Papadimos, MichaelD Walsh

AIMS: The utility of GATA3 immunohistochemistry (IHC) as an aid to the cytological diagnosis of metastatic breast carcinoma in fine needle aspiration (FNA) specimens was investigated. MATERIALS AND METHODS: Cell block sections from 111 FNA cases of metastatic malignancy were stained for …

au (code pays fourni par la source)

Approach to thyroid cytology: rationale for standardisation

M. Priyanthi Kumarasinghe, Margaret C. Cummings, Wendy A. Raymond, Paul Shield et autres

au, sg (code pays fourni par la source)

Rapid on‐site evaluation of fine needle aspiration specimens by cytology scientists: a review of 3032 specimens

Paul Shield, J. Cosier, G. Ellerby, M. Gartrell et autres

OBJECTIVES: To determine: (1) the accuracy of cytology scientists at assessing specimen adequacy by rapid on-site evaluation (ROSE) at fine needle aspiration (FNA) cytology collections; and (2) whether thyroid FNA with ROSE has lower inadequacy rates than non-attended FNAs. METHODS: The ROSE …

au (code pays fourni par la source)